Amazon Pharmacy has begun offering Eli Lilly’s GLP-1 medication, Foundayo, via same-day delivery. The once-daily oral treatment is approved for adults with obesity or overweight with weight-related conditions. Patients with a valid prescription can order the drug with real-time pricing…
GLP-1s
Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…
The FDA has clarified its policies regarding GLP-1s, stating that pharmacies must stop compounding GLP-1 drugs once branded versions are removed from the agency’s shortage list, signaling a narrower pathway for producing the high-demand therapies as supply stabilizes. Under federal…
The FDA on April 1 approved Eli Lilly’s daily GLP-1 pill, Foundayo, making it the U.S. market’s second oral GLP-1 drug for treating obesity. The first oral GLP-1 approved for weight loss is Novo Nordisk’s Wegovy pill (semaglutide), which the…
Novo Nordisk has launched a multimonth subscription program for Wegovy, which claims to offer more predictable, lower pricing for eligible self-pay patients who enroll through select telehealth providers. The program is currently available through Ro, WeightWatchers and LifeMD. Additional platforms,…
Advertisement
New Haven, Conn.-based Yale researchers are studying whether GLP-1 drugs may extend beyond diabetes and obesity treatment to address addiction, NBC Connecticut reported March 27. Rajita Sinha, PhD, director of the Yale Interdisciplinary Stress Center, studied semaglutide in people with obesity and…
GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are FDA-approved for diabetes and weight loss, but growing evidence suggests their effects may extend beyond blood sugar and body fat, according to a March 27 analysis by The Washington Post. Researchers…
Use of GLP-1 receptor agonists — including drugs such as Wegovy, Ozempic, Mounjaro and Zepbound — continues to reshape treatment patterns for obesity, diabetes and beyond. Several March studies and surveys highlight how these medications are shifting patient behavior, influencing…
A March analysis from KFF aims to shed light on CMS’ upcoming BALANCE model for GLP-1 coverage — highlighting financial requirements, operational mandates and unresolved policy questions — ahead of its 2027 launch. The model, announced in December, builds on the…
Cost is not the primary barrier keeping Americans from weight loss drugs, despite historically high list prices and inconsistent insurance coverage, according to a March 17 Axios-Ipsos poll. The finding is based on survey responses from a nationally representative sample…